The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Eli Lilly ( LLY 2.45%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival. That ...

The man in his 40s, who was not identified, had been on the carnivore diet for 8 months when he started to notice the discoloration on the palms of his hands, his elbows and the soles of his feet, ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...